CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis

(c) 2010 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 136(2010), 1 vom: 03. Juli, Seite 139-47
1. Verfasser: Richter, J (VerfasserIn)
Weitere Verfasser: Benson, V, Grobarova, V, Svoboda, J, Vencovsky, J, Svobodova, R, Fiserova, A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoantibodies Autoantigens Glucocorticoids Glycoconjugates Immunosuppressive Agents NK Cell Lectin-Like Receptor Subfamily B Polysaccharides Vimentin mehr... N-Acetylglucosaminyltransferases EC 2.4.1.- alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase EC 2.4.1.155 Hydrolases EC 3.- PADI4 protein, human EC 3.5.3.15 Protein-Arginine Deiminase Type 4 Protein-Arginine Deiminases
LEADER 01000naa a22002652 4500
001 NLM197045391
003 DE-627
005 20231223205740.0
007 cr uuu---uuuuu
008 231223s2010 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2010.03.005  |2 doi 
028 5 2 |a pubmed24n0657.xml 
035 |a (DE-627)NLM197045391 
035 |a (NLM)20359956 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Richter, J  |e verfasserin  |4 aut 
245 1 0 |a CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis 
264 1 |c 2010 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 06.08.2010 
500 |a Date Revised 10.12.2019 
500 |a published: Print-Electronic 
500 |a ErratumIn: Clin Immunol. 2015 Mar;157(1):102 
500 |a Citation Status MEDLINE 
520 |a (c) 2010 Elsevier Inc. All rights reserved. 
520 |a We investigated the role of natural killer (NK) cells and CD161, their primary C-type-lectin-like receptor in rheumatoid arthritis (RA). Samples were compared with healthy donors (HD), dermatomyositic (DM), polymyositic (PM), and osteoarthritic (OA) patients. RA, PM, and DM NK cell cytotoxicities significantly decreased relative to the HD and OA NK cells (p<0.0001). These results correlated with an increased expression of NK cell inhibitory receptor CD161, in active disease RA patients. We demonstrated that NK cells are able to respond to mutated citrullinated vimentin (MCV), an RA-specific autoantigen, leading to increases in both PAD4 enzyme and CD161 mRNA expression. MGAT5 glycosidase involvement was detected in GlcNAc metabolism within the synoviocytes of RA patients. Our findings reveal a functional relationship between CD161 expression and NK cell cytotoxicity as well as reactivity to glycans and MCV, thus providing new insight into the pathogenesis of RA and confirming the involvement of surface glycosylation 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Autoantigens  |2 NLM 
650 7 |a Glucocorticoids  |2 NLM 
650 7 |a Glycoconjugates  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a NK Cell Lectin-Like Receptor Subfamily B  |2 NLM 
650 7 |a Polysaccharides  |2 NLM 
650 7 |a Vimentin  |2 NLM 
650 7 |a N-Acetylglucosaminyltransferases  |2 NLM 
650 7 |a EC 2.4.1.-  |2 NLM 
650 7 |a alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase  |2 NLM 
650 7 |a EC 2.4.1.155  |2 NLM 
650 7 |a Hydrolases  |2 NLM 
650 7 |a EC 3.-  |2 NLM 
650 7 |a PADI4 protein, human  |2 NLM 
650 7 |a EC 3.5.3.15  |2 NLM 
650 7 |a Protein-Arginine Deiminase Type 4  |2 NLM 
650 7 |a EC 3.5.3.15  |2 NLM 
650 7 |a Protein-Arginine Deiminases  |2 NLM 
650 7 |a EC 3.5.3.15  |2 NLM 
700 1 |a Benson, V  |e verfasserin  |4 aut 
700 1 |a Grobarova, V  |e verfasserin  |4 aut 
700 1 |a Svoboda, J  |e verfasserin  |4 aut 
700 1 |a Vencovsky, J  |e verfasserin  |4 aut 
700 1 |a Svobodova, R  |e verfasserin  |4 aut 
700 1 |a Fiserova, A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 136(2010), 1 vom: 03. Juli, Seite 139-47  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:136  |g year:2010  |g number:1  |g day:03  |g month:07  |g pages:139-47 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2010.03.005  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 136  |j 2010  |e 1  |b 03  |c 07  |h 139-47